专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO1983003201A1 METHODS OF TREATING THE EYE WITH LIQUID PERFLUOROCARBONS 审中-公开
标题翻译：用液体全氟化合物治疗眼睛的方法
公开(公告)号：WO1983003201A1
公开(公告)日：1983-09-29
申请号：PCT/US1983000336
申请日：1983-03-14
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , CLARK, Leland, C., Jr.
IPC分类号： A61K49/04
CPC分类号： A61K31/025 , A61L27/00 , A61L2430/16
摘要： Des hydrocarbures perfluorés liquides et leurs dérivés substitués sont utilisés pour remplacer les fluides du corps vitreux ou de l'humeur aqueuse de l'oeil. Ces liquides sont également utilisés pour rétablir la transparence de la cornée du cristallin lorsque ceux-ci deviennent opaques à la suite d'une dégénerescence ou de la formation de cataracte. L'invention porte également sur des procédés d'utilisation de ces liquides lors d'interventions chirurgicales sur la rétine ou dans des procédures de diagnostic optique.

12. 发明申请

WO1998039355A1 SPECIES-SPECIFIC YEAST TFIIB SEQUENCE 审中-公开
标题翻译：物种特异性YEAST TFIIB序列
公开(公告)号：WO1998039355A1
公开(公告)日：1998-09-11
申请号：PCT/US1997010404
申请日：1997-06-13
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , MA, Jun , SHAW, Shruti , CARSON, Daniel, J. , DORSEY, Michael, J. , WINGFIELD, Jonathan
IPC分类号： C07H21/04
CPC分类号： C07K14/40 , G01N33/56961
摘要： An extended species-specific sequence region of yeast transcription factor IIB (yTFIIB) (amino acids 144-157) is critical for cell viability and gene activation. Four residues in yTFIIB, Lys-147, Cys-149, Lys-151, and Glu-152, are critical for yeast cell growth. Intragenic suppressor experiments identified mutations that reversed, or partially reversed, the temperature sensitive phenotype of a yTFIIB derivative bearing amino acid changes at these four positions to human residues. Some of these residues (positions 115, 117 and 182) are located outside the species-specific region of yTFIIB. The identification of this species-specific region provides a unique and specific target for antifungal drugs and a screening assay therefor.
摘要翻译：酵母转录因子IIB（yTFIIB）（氨基酸144-157）的扩展种特异性序列区域对于细胞活力和基因激活是关键的。 yTFIIB，Lys-147，Cys-149，Lys-151和Glu-152中的四个残基对酵母细胞生长至关重要。诱变抑制实验确定了将这四个位置的含有氨基酸的yTFIIB衍生物的温度敏感表型逆转或部分逆转到人类残基的突变。这些残基中的一些（位置115,117和182）位于yTFIIB的物种特异性区域之外。鉴定该物种特异性区域为抗真菌药物提供了独特且具体的靶点及其筛选试验。

13. 发明申请

WO1997045108A1 GUANIDINO DERIVATIVES AS INHIBITORS OF THE CYTOTOXIC EFFECT OF PEROXYNITRITE 审中-公开
标题翻译：作为过氧化物的细胞毒性作用的抑制剂的胍苷衍生物
公开(公告)号：WO1997045108A1
公开(公告)日：1997-12-04
申请号：PCT/US1997008280
申请日：1997-05-16
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , SOUTHAN, Garry, J. , SALZMAN, Andrew, L. , SZABO, Csaba
IPC分类号： A61K31/155
CPC分类号： A61K31/155
摘要： This invention is directed to a pharmacologically acceptable composition for inhibiting the cytotoxic effect of peroxynitrite in a mammal, which includes a guanidino derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting the cytotoxic effect of peroxynitrite, and treating various conditions where there is an advantage in inhibiting the cytotoxic effect of peroxynitrite. The method includes the step of administering to a mammal a guanidino derivative in pure form or in a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及用于抑制哺乳动物中过氧亚硝酸盐的细胞毒性作用的药学上可接受的组合物，其包括胍基衍生物和药学上可接受的载体。本发明还涉及一种抑制过氧亚硝酸盐的细胞毒性作用的方法，以及治疗在抑制过氧亚硝酸盐的细胞毒性作用方面具有优势的各种条件。该方法包括向哺乳动物施用纯形式的胍基衍生物或药学上可接受的载体的步骤。

14. 发明申请

WO1997041857A1 COMPOSITION COMPRISING A KATP CHANNEL INHIBITOR FOR USE IN THE TREATMENT OF HEMORRHAGIC SHOCK 审中-公开
标题翻译：包含KATP通道抑制剂用于治疗HEMORRHAGIC震动的组合物
公开(公告)号：WO1997041857A1
公开(公告)日：1997-11-13
申请号：PCT/US1997006790
申请日：1997-04-24
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , SALZMAN, Andrew, L. , SZABO, Csaba
IPC分类号： A61K31/445
CPC分类号： A61K31/7076 , A61K31/15 , A61K31/155 , A61K31/235 , A61K31/4164 , A61K31/4402 , A61K31/4458 , A61K31/513 , A61K31/5415 , A61K31/64 , A61K45/06 , Y10S514/921
摘要： This invention is directed to a pharmacologically acceptable composition for inhibiting or treating hemorrhagic shock in a mammal. The composition includes a KATP inhibitor and a pharmacologically acceptable carrier, with the KATP inhibitor being present in an amount sufficient to inhibit or treat hemorrhagic shock in the mammal. The invention is also directed to a method for inhibiting or treating hemorrhagic shock in a mammal. The method includes administering to the mammal an amount of a KATP channel inhibitor sufficient to inhibit or treat hemorrhagic shock in the mammal. In a preferred form of the invention, the KATP channel inhibitor is selected from the group consisting of sulfonylurea, a guanidine, a phenothiazine, an imidazoline, TMB-8 (8-N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate, 2,3-butanedione monoxime, disopyramide, gliquidone, chlorpromazine, AMP-NPP, flecainide, MS-551 and combinations thereof.
摘要翻译：本发明涉及用于抑制或治疗哺乳动物出血性休克的药理学上可接受的组合物。组合物包括KATP抑制剂和药理学上可接受的载体，KATP抑制剂以足以抑制或治疗哺乳动物的出血性休克的量存在。本发明还涉及用于抑制或治疗哺乳动物的出血性休克的方法。该方法包括向哺乳动物施用足量抑制或治疗哺乳动物出血性休克的量的KATP通道抑制剂。在本发明的优选形式中，KATP通道抑制剂选自磺酰脲，胍，吩噻嗪，咪唑啉，TMB-8（8-N，N-二乙基氨基）辛基-3,4,5- 三甲氧基苯甲酸酯，2,3-丁二酮一肟，丙吡胺，格列酮酮，氯丙嗪，AMP-NPP，氟卡尼定，MS-551及其组合。

15. 发明申请

WO1993006875A1 HEMOFILTRATION SYSTEM AND METHOD 审中-公开
标题翻译： HEMOFILTRATION系统和方法
公开(公告)号：WO1993006875A1
公开(公告)日：1993-04-15
申请号：PCT/US1992008495
申请日：1992-10-06
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , KITAEVICH, Yuli , HEMASILPIN, Nat , MARCHEVSKY, J., Gabriel , BISSLER, John, J. , BENZING, George, III , McENERY, Paul, T.
IPC分类号： A61M01/16
CPC分类号： A61M1/16 , A61M1/1643 , A61M1/34 , A61M1/341 , A61M1/3427 , A61M1/3451 , A61M1/3607 , A61M2205/15 , A61M2205/3331 , A61M2205/3334 , A61M2205/3344 , A61M2205/3368 , A61M2205/3393 , A61M2205/50 , Y10S210/929
摘要： A multipurpose hemofiltration system (10) and method are disclosed for the removal of fluid and/or soluble waste from the blood of a patient. The system (10) and method are equally applicable to adult, pediatric and neonatal patients. The system (10) continuously monitors the weight of infusate in a first reservoir (50) and drained fluid (76) in a second reservoir (74) and compares those weights to corresponding predetermined computed weights. When necessary, the pumping rates of the infusate (52), drained fluid (76) and blood are adjusted in order to achieve a preselected amount of fluid removal from the patient's blood in a preselected time period. Application of this system (10) and method provide repeatable and highly precise results.

16. 发明申请

WO1991013973A1 MEGAKARYOCYTIC IN VITRO CELL LINE 审中-公开
标题翻译：体细胞细胞系中的巨噬细胞
公开(公告)号：WO1991013973A1
公开(公告)日：1991-09-19
申请号：PCT/US1991001301
申请日：1991-02-28
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , UNIVERSITY OF CINCINNATI
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , UNIVERSITY OF CINCINNATI , LIEBERMAN, Michael, A. , FUGMAN, Douglas, A.
IPC分类号： C12N05/08
CPC分类号： C07K14/495 , C07K14/503 , C12N5/0644 , C12N2502/1394
摘要： Human monophenotypic cloned cell lines of megakaryocytic lineage are established in vitro through use of adherent stromal cells in long term human bone marrow culture. One cloned in vitro cell line, CHRF-288-11, exhibits a karyotype and markers characteristic of megakaryocytes and platelets. CHRF-288-11 cells express platelet peroxidase, platelet factor IV, platelet CA -ATPase, gpIIbIIIa, factor VIII, and MY7, MY9 and HLA-Dr antigens. CHRF-288-11 cell lines do not express erythroid markers glycophorin A and hemoglobin, myeloid marker myeloperoxidase, nor markers specific for T- and B-cells. CHRF-288-11 cells also express basic FGF and TGF-beta properties. CHRF-288-11 cells exhibit a constant karyotype (50, XY) and displays a doubling time of approximately 33 hours in either 25 % horse or calf serum. Treatment of CHRF-288-11 cells with phorbol 12-myristate 13-acetate (PMA) induces multi-nucleation and hyperploidy with about 35 % of the cells exhibiting two or more nuclei per cell, and greater than 80 % of the cells enlarging in size. CHRF-288-11 cell line is deposited under the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, under accession no. CRL 10107.
摘要翻译：通过在长期人类骨髓培养物中使用贴壁基质细胞体外建立巨核细胞谱系的人类单克隆克隆细胞系。一个克隆的体外细胞系CHRF-288-11表现出核型和巨核细胞和血小板特征的标记。 CHRF-288-11细胞表达血小板过氧化物酶，血小板因子IV，血小板CA ++，ATP酶，gpIIbIIIa，因子VIII和MY7，MY9和HLA-Dr抗原。 CHRF-288-11细胞系不表达红细胞标志物血型糖蛋白A和血红蛋白，骨髓标志物髓过氧化物酶，也不表示特异于T细胞和B细胞的标志物。 CHRF-288-11细胞也表达基本的FGF和TGF-β特性。 CHRF-288-11细胞表现出恒定的核型（50，XY），在25％的马或小牛血清中显示约33小时的倍增时间。用佛波醇12-肉豆蔻酸酯13-乙酸酯（PMA）处理CHRF-288-11细胞诱导多核和超倍性，约35％的细胞每个细胞呈现两个或更多个细胞核，大于80％的细胞扩大尺寸。 CHRF-288-11细胞系根据布达佩斯条约与美国典型培养物保藏中心共享，12301 Parklawn Drive，Rockville，Maryland 20852，登录号： CRL 10107。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式